Dayzz Sleep App Announces Publication of the Findings From Clinical Trial to Validate Its Sleep Assessment Machine Learning Engine

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

June 25, 2020

Innovative sleep solution provider dayzz announced this week the results of its first clinical trial. dayzz’ machine learning engine enables assessment of common sleep disturbances using a proprietary questionnaire. The clinical trial was conducted in collaboration with the Johns Hopkins Center for Interdisciplinary Sleep Research and Education.

In the U.S., more than 30% of the adult population suffer from sleep problems, and it is estimated that 50-70 million Americans have a sleep disorder that affects their health and quality of life. Many of them are undiagnosed and untreated. Insufficient sleep alone costs the US economy over $400 billion a year, and sleep problems among employees have huge financial implications on employers and payers. dayzz has developed and validated the Digital Sleep Questionnaire (DSQ) to identify common societal sleep disturbances including insomnia, delayed sleep phase syndrome, insufficient sleep syndrome, and risk for obstructive sleep apnea.

“dayzz’ machine learning algorithm was trained on gold-standard sleep expert diagnoses of people in the community with common sleep complaints and has shown high accuracy in predicting those at risk for prevalent sleep disorders,” said Dr. Mairav Cohen-Zion, Chief Science Officer at dayzz. “This is a critical step forward for dayzz in identifying sleep disorders at scale and offering a personalized sleep training experience for our users.”

In the upcoming months, dayzz will launch a randomized clinical trial in collaboration with researchers at Brigham and Women’s Hospital and Harvard Medical School to examine the effectiveness of its solution in a large community-based organizational setting. Read more here.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.